INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor)
View HTML
Toggle Summary NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D ., Executive Chairman of the Board of Directors, will participate in the 39 th Annual J.P.
View HTML
Toggle Summary ImmunityBio Simulates SARS-CoV-2 Spike Protein Binding Using Molecular Dynamics
Detailed computer modeling, completed in partnership with Microsoft, explains virulence of COVID-19 and provides key information that may lead to a better understanding of the multiple mutations currently occurring to the “spike” protein as the virus evolves Computer-based molecular dynamics
View HTML
Toggle Summary ImmunityBio Appoints Fabio M. Benedetti, M.D. as Chief Strategy Officer
Dr. Benedetti Brings More Than 20 Years in Oncology Clinical Development and Global Large Pharma Experience  CULVER CITY, Calif., December 30, 2020 –  ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D.
View HTML
Toggle Summary ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease programs for HIV and COVID-19
View HTML
Toggle Summary ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates
BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The second-generation human
View HTML
Toggle Summary ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- ImmunityBio, a privately-held immunotherapy company, today announced the publication in
View HTML
Toggle Summary NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
EL SEGUNDO, Calif. --(BUSINESS WIRE)--Nov. 18, 2020-- NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32 nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020 .
View HTML
Toggle Summary ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design   CULVER CITY, Calif. & EL SEGUNDO, Calif. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2
Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells Study results suggest
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.